Morphine 0.125mgkg~' was administered i.v. to 11 normal subjects and nine patients with chronic renal failure requiring regular haemodialysis. Plasma morphine concentrations were measured using high pressure liquid chromatography (HPLC). Although there was considerable individual variation in both groups, mean plasma concentrations of morphine were significantly higher in the patients with renal failure for 15 min after administration. The decay of plasma concentration fitted a three-compartment mamillary pharmacokinetic model in all subjects. Derived values (mean + SEM) of Tj 1 , volume of distribution of the second compartment (Vi), total volume of distribution at steady state ( V™ 1 ) and transfer rate constant from the first to the second compartment (4i2)> were significantly different between groups. Mean values of terminal elimination half-life (Tj 1 ) and total body clearance were similar in the two groups. It was concluded that elimination of unchanged morphine is not impaired significantly in patients with chronic renal failure, although accumulation of morphine-3-glucuronide probably occurs. Although the pharmacological effect of morphine is not related temporally to plasma morphine concentrations, the higher values in patients with renal failure may be implicated in their increased sensitivity to the drug.
The phannacokinetics of i.v. morphine have been described in normal subjects (Brunk and Delle, 1974; Stanski, Greenblatt and Lowenstein, 1978; Yang et al., 1979) , in patients with malignant disease (Sawe et al., 1981) , and in children (Dahlstrom et al., 1979) and adults undergoing surgery (Berkowitz et al., 1975; Stanski, Greenblatt and Lowenstein, 1978; Murphy and Hug, 1981) . However, as a result of different methodology, particularly analytical techniques and their specificity for unchanged morphine, there remains some controversy regarding the disposition of the drug.
Although hepatic metabolism is responsible for most of the clearance of morphine from the body (Jaffe and Martin, 1980) , it has been claimed from clinical studies that patients suffering from chronic renal failure are more sensitive than normal subjects to the pharmacological effects of morphine, and that its duration of action in such patients is prolonged (Don, Dieppa and Taylor, 1975) . The purpose of the present study was to compare the pharmacokinetics of i.v. morphine in normal subjects and in patients in end-stage renal failure.
Eleven healthy subjects (six male), mean age 30.6 yr (range 24-40yr) and mean weight 62.6kg (range 47-85 kg), were compared with nine patients (five male) with chronic renal failure (mean age 30 yr (range 22-55yr) and mean weight 58.7 kg (range 38-83 kg)). All had fasted for 6h before the study, and the patients with renal failure had undergone haemodialysis in the previous 10-24 h. The study was passed by the District ethics committee, and informed consent was obtained from those taking part.
A cannula was inserted to a vein in the antecubital fossa, and morphine sulphate0.125 mgkg" 1 inO.9% saline 10 ml was injected i.v. over 30 s. Venous blood was sampled at 0.5, 2, 5, 10, 15, 20, 30, 40, 60, 90 and 120 min after injection of morphine. The blood was centrifuged immediately, and plasma stored at -70°C until required for analysis.
Analysis for morphine
Analyses were performed in duplicate. One millilitre of plasma was mixed with sodium chloride 1 g. To this was added 100 ulitre of nalorphine 250ngml~I as internal standard, and the pH of the plasma was adjusted to 8.2 by addition of borate buffer. After the addition of chloroform 9 ml, the sample was shaken mechanically for 15 min, and centrifuged at 3000 rev min-1 for 5 min The aqueous layer was aspirated and the chloroform layer removed and evaporated under nitrogen at 60 °C. The composition of the mobile phase was 0.08-jnol litre" 1 potassium dihydrogen orthophosphate 1000 ml, methanol 200 ml and heptane sulphonic acid 2 ml. The extracted residue was dissolved in 120 jditre of mobile phase. The column consisted of reverse-phase u-Bondapak Cu, 25 cm in length and 4.4mm i.d. The flow rate through the column was 1.5 ml min" 1 , and an electrochemical detector at 0.64 V was used to measure morphine concentrations. Recovery of morphine from plasma standards was 100.9 ± 0.5% (mean ± SEM). The coefficient of variation of the assay was less than 5%. The lower limit of sensitivity of the assay was approximately Ing ml" 1 .
Data processing
The plasma morphine-time data were fitted by computer after preliminary exponential stripping to bi-and tri-exponential equations using weighted non-linear least-square regression analysis. Weights of 1, 1/C and l/Q 2 , where C, = concentration at time t, were used. The optimal choice of weighting was made for each set of data on the basis of several criteria: values of the coefficient of determination (r 2 ), weighted residual plots, plots of the observed values with the model-predicted line drawn through the points, and standard deviations of the estimated parameters (Wagner, 1975) . The choice of a two-or three-compartment model was determined by Fratio testing. Elimination half-lives, volumes of distribution, total body clearance and the apparent intercompartmental transfer rate constants were calculated using standard formulae (see Appendix). Significance of differences between the two groups was evaluated using the Wilcoxon rank sum test for non-parametric data. Figure 1 shows mean plasma morphine concentration-time curves for both groups. Concentrations of morphine were significantly greater in the patients with renal failure for 15 min after administration. Thereafter, the mean concentration decay curves tended to converge, although the mean morphine concentration remained higher in the pa- dents with renal failure. There was a wide range of plasma morphine concentrations in both groups (table I) . A tri-exponential curve was found to provide the best fit for data from all subjects. The coefficients of determination exceeded 0.998 for all normal subjects, and 0.989 for all the renal patients. Table II contains the derived pharmacokinetic parameters for each group. The mean half-life of the initial redistribution phase (7}") was significantly longer in the patients with renal failure. Mean terminal elimination half-lives and total body clearances were not significantly different between the two groups. Mean volumes of distribution were greater in the normal subjects, but the differences were statistically significant only for V 2 and V m . The transfer rate constant k i2 was significantly greater in the normal subjects than in the patients with renal failure.
RESULTS

DISCUSSION
Most previous studies of the disposition of morphine have measured plasma concentrations using radioimmunoassay (RIA). This technique is not specific for morphine, as the antisera used detect a proportion of morphine-3-glucuronide, the principal hepatic metabolite of morphine. Plasma concentrations of the glucuronide exceed those of morphine within lOmin of i.v. administration and, by 90 min, the concentration of unchanged morphine is less than 10% of the total morphine detectable (Murphy and . Thus, an RIA technique with even 1 % cross-reactivity with morphine glucuronide is likely to lead to sizeable errors in estimation of plasma morphine concentrations. Catlin (1977) demonstrated that there may be considerable variation in the degree of cross-reactivity of different batches of RIA antisera with morphine and its metabolites. If morphine is extracted before estimation, recovery of morphine may be less than 100%, and contamination with glucuronide may still occur.
In the present study morphine concentrations were measured in comparison with a known standard (nalorphine) added to each sample. Thus, the estimation of morphine was independent of the absolute extraction from the plasma sample. The electrochemical detector used in the oxidation mode oxidizes phenolic hydroxyl groups, and detection is based on the change in voltage produced by this oxidation. As the glucuronide residue occupies the site occupied by the phenolic hydroxyl group on the morphine molecule, this method of detection is completely insensitive to morphine glucuronide, and measures only unchanged morphine.
Mean morphine concentrations at 30, 60, and 120 min after administration of morphine 0.125-0.14 mg kg" 1 i.v. in several studies, are shown in table in. Except for the study by Stanski, Greenblatt and Lowenstein (1978) , mean morphine concentrations were much higher in those investigations in which RIA was used without solvent extraction.
In the present study, we took samples for 2 h after administration of morphine. This relatively short sampling period could result in an error in the estimation of terminal elimination half-life. However, Bullingham and others (1982) , in a study of the pharmacokinetics of methadone, showed that prolonged sampling did not necessarily lead to better estimates of derived parameters. In addition, the value for terminal elimination half-life in the present study is very similar to that obtained in unanaesthetized subjects by Stanski, Greenblatt and Lowenstein (1978) , who sampled blood for 48 h after morphine administration.
The values of elimination half-lives, distribution volumes and clearance rate for normal subjects in the present study are compared in table IV with those published by other groups. Estimations of distribution volumes and clearances vary more widely than those of elimination half-lives. Differences may reflect the specificity of analytical techniques used, the age and physical status of the subjects and the effects of anaesthesia and surgery.
A number of theories have been proposed for the wide individual variation in distribution of morphine, including unequal miving in plasma after injection, variations in plasma protein binding and tissue blood flow and differences in the volaemic status of the subjects. The first and second elimination phases probably represent distribution of morphine to tissues and organs. The longer Tf found in our patients with renal failure may reflect differences in haemodynamics and organ perfusion compared with normal subjects. The smaller distribu- tion volumes found in patients with renal failure may be related to altered haemodynamics, or to the reduced total body water and altered protein binding found in patients with chronic renal failure who have undergone haemodialysis (Olsen, Bennett and Porter, 1975) . However, as with all pharmacokinetic models, the calculation of volumes of distribution does not imply that specific sites of distribution are known, and therefore differences occurring in separate goups of patients are difficult to interpret. The terminal elimination half-lif e, which depends on both the volume of distribution and the total body clearance rate, is particularly important if doses of the drug are to be repeated, since accumulation is more likely to occur in the presence of a prolonged elimination half-life. The mean clearance rate in the patients with renal failure was approximately 10% less than that in the normal subjects, corresponding, possibly fortuitously, with the percentage of unchanged morphine normally excreted by the kidneys (Berkowitz, 1976) . It is likely, however, that concentrations of morphine-3-glucuronide, which is excreted predominantly in the urine, will accumulate in the plasma of anuric patients. Morphine glucuronide penetrates into cerebrospinal fluid in the dog , and intracerebral injections of morphine glucuronide have been shown to produce analgesia and respiratory depression (Sasajima, 1970) .
Plasma morphine concentration is known not to correlate well with pharmacological activity of morphine after bolus injection, probably because of a delay in penetration of the blood-brain barrier, and a further delay in receptor binding. Cerebrospinal fluid concentrations of morphine peak 15-30min after i.v. injection , and decay more slowly than plasma concentrations. Respiratory depression reaches a maximum 30-60 min after administration. Similarly, analgesia has been found to reach a maximum about 1S min after peak brain concentrations of morphine, and subsequently to decline more slowly (Dahlstrom and Paalzow, 1978) . Thus, the analgesic effect and respiratory side-effects of morphine may not be evident during the initial high plasma concentrations resulting from i.v. administration, but may persist despite decreasing plasma concentrations during the terminal elimination phase. In the present study, however, mean plasma concentrations remained greater in the patients with renal failure than in the normal subjects for 2 h, suggesting that, irrespective of the time relationship between plasma concentrations and central effect, patients with chronic renal failure may, on average, show more sensitivity to the pharmacological effects of morphine.
In conclusion, we have found that the distribution and elimination of morphine administered i.v. to normal subjects and patients with chronic renal failure resulted in a tri-exponential decay of plasma morphine concentrations. There was wide variation between individuals but, on average, patients with renal failure exhibited higher plasma concentrations after injection, and smaller distribution volumes, which might result in increased sensitivity to the effects of the drug. Elimination from the body was not significantly reduced in patients with renal failure, and it would appear that accumulation of morphine is not likely to' occur to a significantly greater degree in such patients than in normal subjects.
APPENDIX
After i.v. injection, the decay in plasma morphine concentration was fitted best by a tri-exponential equation using the method of residuals (Gibaldi and Perrier, 1975 ) to obtain estimated parameters, and an iterative computer program was used to find the best-fit curve using non-linear least squares regression analysis. The intercompartmental transfer rate constants (*io, *12. *2l> *i3i *3i), apparent volumes of distribution of the central compartment (VO and the two peripheral compartments (Vj, V3), the total apparent volume of distribution (V**), the total volume of distribution at steady state (V"), and the total body clearance (CD were calculated from standard formulae (Hull, 1979) . V* is a proportionality constant relating the amount of drug in the body to the plasma concentration at any tim^ during the *\iminaticm phase. It is dependent on the value of *io> *nd it only an approximate index of total distribution volume. V is the sum of the individual compartmental volumes (V\ + Vi + Vj) (Klotz, 1976 Seadministro 0,125 mg kg' 1 demorfinai.v. all mjetosnormalet y a nuevc pacicntcs con falla renal cronica quc ncccsitaban hemodialisia regular. Se midieron las '^"^'^'trarionfft de morfina en el plasma al u*ar CTomatografia liquida bajo alta preti6n (HPLC). Aunquc se registraron variaciones individualcs considerablei en ambos grupos, Us concentraciones media* de morfina en el plasma se encontnban mucho mayore* en los pacientes con falla renal durantee 15 niin dcspuis de la administracion. El deterioro de la concentracion en el pimtma <oi'i'g^|vwiHtfl a un modelo farmacotinetico mamilar de tres comparmnientos en todos los sujetos. Hubo diferencias tignificativas entre los grupos en lo que se refiere a los valores derivados (SEM promedio) del volumen 3}", de distribution del segundo comptmmiento (Vj), del volumen total de distribution con ritmo estable (V) y de la constantc H^l ritmo de tnuuferencia del primer compartmiiento al HfyindA (fcii)* Los valores promedios de Tnrdrt vida de ftimhw. cion terminal (T) 7 ) y la riiminarion corporal total eran analogos en ambos grupos. Se concluyo que la ^liTwinofiAn de 1A morfina no~cambiada no se halla impedida de manera fiff"'fi**^"t^ en los pacientes que padecen de falla renal cronica, aunque se produzca probablemente una acumulacion del ghtcuronido-3-morfina. No obttante el hecho de que el efecto farmacologico de la morfina no tcnga rclacidn de tiempo con las rnnryriTranonft de morfina en el plasma, es posible que los valores mas altos en pacientes con falla renal dejen pensar que esos tienen que ver con su mayor sensibilidad a Hirhn substancia.
